FRANCE Law and Practice Contributed by: Emmanuelle Trombe, Anthony Paronneau, Anne-France Moreau and Lorraine Maisnier-Boché, McDermott Will & Emery
McDermott Will & Emery is ranked among the top life sciences and health law firms and op- erates from over 20 locations with more than 1,400 lawyers delivering highly effective solu- tions across practices and geographies. The global Life Sciences practice group provides critical guidance to leading life sciences com- panies and investors. With 160+ lawyers in the US and Europe, the team advises biotechnol- ogy, pharmaceutical and medical technology
companies on complex FDA/regulatory, trans- actional, intellectual property and litigation mat- ters. The team offers solid experience and crea- tive solutions and the firm represents 75% of the top 20 biopharmaceutical companies glob- ally. A special thanks to associates, Caroline Noyrez, Nejma Palasse and Julie Favreau, as well as trainee Virginie Guelé, for their invaluable sup- port.
Authors
Emmanuelle Trombe is a partner at McDermott Will & Emery and co-heads the firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and
Anthony Paronneau is a partner at McDermott Will & Emery and advises clients on all aspects of corporate and business law, with a particular focus on the pharmaceutical, medical device,
biopharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio- pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the firm’s Life Sciences group, Emmanuelle serves as an elected member of the firm’s management committee.
biotech and healthcare industries. Anthony has significant experience advising life sciences companies, private equity funds and venture capital firms on a number of M&A and private equity transactions, including acquisitions, financing rounds, joint ventures and divestitures. He also regularly advises life sciences companies on collaborations, licensing and distribution arrangements.
95
CHAMBERS.COM
Powered by FlippingBook